Mydecine Innovations Group Included in First-Ever Psychedelics ETF
Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has been included in the first-ever Psychedelics Exchanged Traded Fund . The Horizons Psychedelic Stock Index ETF index, which was announced in December 2020 and includes 17 companies in the U.S. and Canada, is expected to start …
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has been included in the first-ever Psychedelics Exchanged Traded Fund (ETF).
The first-ever psychedelics ETF will launch next week, backed by a Canadian fund manager Emily Graffeo
Canada-based Horizons ETF Management is launching the first-ever psychedelics ETF.
The Horizons Psychedelic Stock Index ETF (PSYK) will begin trading on the NEO exchange next Wednesday.
.
The first-ever psychedelics ETF will begin trading on the Canadian NEO exchange next Wednesday, giving investors exposure to publicly-traded companies focused on the development of therapeutic solutions that utilise psychedelics.
Canada-based Horizons ETF Management announced Friday that it filed its final prospectus to launch the Horizons Psychedelic Stock Index ETF (PSYK). PSYK will be the world s first exchange traded fund (
Entheon Biomedical Corp.: Entheon Biomedical to be Included in First North American Psychedelic ETF
Vancouver, British Columbia (Newsfile Corp. - January 22, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ( Entheon or the Company ), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce its inclusion in the Horizon North American Psychedelic ETF, the first ever psychedelic ETF of its kind. The new ETF is expected to start trading January 26, 2021 under the symbol PYSK on the NEO exchange.
The Psychedelic ETF invests in North American publicly-listed companies focused on psychedelic medicines, providing diversified exposure to the psychedelics industry, and is designed to reflect the evolution of the industry in a timely fashion. The underlying index of the Psychedelic ETF is the North American Psychedelics Stock Index and measures performance of its constituent companies.
MINDCURE Included in First Psychedelic ETF & North American Psychedelics Index
News provided by
Share this article
Share this article
Mind Cure among respected life science and therapeutic technology peers in first ever Psychedelic ETF & North American Psychedelic Index
VANCOUVER, BC, Jan. 21, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( MINDCURE or the Company ) is pleased to announce its inclusion among 17 psychedelic companies in the first ever Psychedelic ETF. Horizon s Psychedelic ETF, is expected to commence trading Jan. 26, 2021 under ticker PSYK on the NEO exchange.
The ETF includes companies in the Canadian legal psychedelics industry, as well as U.S. companies engaged in legal activities involving psychedelic drugs and substances. The purpose of the ETF is to invest in, and indirectly derive revenues from, companies in the psychedelics industry engaged in legal activities involving psychedelic drugs and substances.